Drug Profile
Research programme: inflammatory disease monoclonal antibodies - Chemomab Therapeutics
Alternative Names: CM-102; CM-301Latest Information Update: 23 Feb 2024
Price :
$50
*
At a glance
- Originator Chemomab Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action CCR3 receptor antagonists; Chemokine CCL 5 inhibitors; Chemokine CCL11 inhibitors; Chemokine CCL24 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders; Inflammation; Rheumatoid arthritis
Most Recent Events
- 02 Jan 2024 Chemomab Therapeutics has patent protection for CM 101 in Brazil related to CM 101 and anti-CCL24 antibodies for the treatment of fibrotic, inflammatory and autoimmune diseases
- 16 Mar 2021 Anchiano Therapeutics has been merged with Chemomab and changed its name to Chemomab Therapeutics
- 20 Nov 2017 Discontinued - Preclinical for Autoimmune disorders in Israel (Parenteral)